BioRestorative Therapies, Inc. (BRTX)
Largest Insider Buys in Sector
BRTX Stock Price History Chart
BRTX Stock Performance
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
Insider Activity of BioRestorative Therapies, Inc.
Over the last 12 months, insiders at BioRestorative Therapies, Inc. have bought $542,791 and sold $995 worth of BioRestorative Therapies, Inc. stock.
On average, over the past 5 years, insiders at BioRestorative Therapies, Inc. have bought $710,546 and sold $7,093 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Broadrick Dale (10 percent owner) — $500,692. Silva Francisco (VP of Research and Development) — $21,227. ALSTODT LANCE (President, CEO, COB) — $20,873.
The last purchase of 6,600 shares for transaction amount of $8,250 was made by Silva Francisco (VP of Research and Development) on 2024‑04‑09.
List of Insider Buy and Sell Transactions, BioRestorative Therapies, Inc.
| 2024-04-09 | Silva Francisco | VP of Research and Development | 6,600 0.0952% | $1.25 | $8,250 | +4.69% | ||
| 2024-04-08 | Silva Francisco | VP of Research and Development | 1,708 0.0228% | $1.16 | $1,979 | +3.91% | ||
| 2024-02-09 | Broadrick Dale | 10 percent owner | 86,041 1.4895% | $1.32 | $113,574 | -0.74% | ||
| 2024-02-08 | Broadrick Dale | 10 percent owner | 157,585 2.6821% | $1.30 | $204,508 | +5.08% | ||
| 2024-02-08 | Broadrick Dale | 10 percent owner | 73,959 1.2124% | $1.25 | $92,449 | +5.08% | ||
| 2024-02-07 | Broadrick Dale | 10 percent owner | 36,374 0.6583% | $1.38 | $50,196 | -5.63% | ||
| 2023-12-01 | Sale | Broadrick Dale | 10 percent owner | 250 0.0053% | $1.88 | $469 | -25.53% | |
| 2023-11-27 | Sale | Broadrick Dale | 10 percent owner | 278 0.0059% | $1.89 | $525 | -26.05% | |
| 2023-09-15 | Broadrick Dale | 10 percent owner | 10,000 0.213% | $1.66 | $16,600 | -4.49% | ||
| 2023-09-15 | ALSTODT LANCE | President, CEO, COB | 2,200 0.048% | $1.70 | $3,740 | -4.49% | ||
| 2023-09-14 | Broadrick Dale | 10 percent owner | 10,000 0.2062% | $1.54 | $15,400 | 0.00% | ||
| 2023-09-13 | ALSTODT LANCE | President, CEO, COB | 800 0.0161% | $1.53 | $1,226 | +6.67% | ||
| 2023-09-07 | Broadrick Dale | 10 percent owner | 2,000 0.044% | $1.86 | $3,720 | -15.34% | ||
| 2023-09-06 | ALSTODT LANCE | President, CEO, COB | 2,887 0.0638% | $1.96 | $5,659 | -15.79% | ||
| 2023-08-31 | Silva Francisco | VP of Research and Development | 4,954 0.1071% | $2.22 | $10,998 | -26.93% | ||
| 2023-07-28 | Broadrick Dale | 10 percent owner | 500 0.016% | $2.89 | $1,445 | -40.88% | ||
| 2023-07-27 | Broadrick Dale | 10 percent owner | 1,000 0.031% | $2.80 | $2,800 | -33.68% | ||
| 2023-07-25 | ALSTODT LANCE | President, CEO, COB | 4,200 0.1134% | $2.44 | $10,248 | -30.45% | ||
| 2023-03-31 | Silva Francisco | VP of Research and Development | 747 0.0216% | $3.56 | $2,659 | -42.79% | ||
| 2023-02-22 | Broadrick Dale | 10 percent owner | 6,000 0.1607% | $2.86 | $17,150 | -16.10% |
Insider Historical Profitability
| Broadrick Dale | 10 percent owner | 477972 10.1547% | $2.02 | 79 | 3 | <0.0001% |
| ALSTODT LANCE | President, CEO, COB | 189505 4.0261% | $2.02 | 33 | 0 | <0.0001% |
| Silva Francisco | VP of Research and Development | 155759 3.4979% | $2.02 | 21 | 1 | <0.0001% |
| Westbury Trust | 10 percent owner | 3115000 66.1792% | $2.02 | 1 | 0 | |
| Desmarais John M | 455000 9.6666% | $2.02 | 2 | 0 | ||
| Tonna Paul Jude | director | 123850 2.6312% | $2.02 | 4 | 0 | |
| Weinreb Mark | CEO and Chairman of the Board | 117000 2.4857% | $2.02 | 5 | 0 | |
| Swiader Joseph B | director | 100000 2.1245% | $2.02 | 1 | 0 | |
| CATELL ROBERT B | director | 80866 1.718% | $2.02 | 3 | 0 | |
| Radov A. Jeffrey | director | 24500 0.5205% | $2.02 | 4 | 0 | |
| Ryan Charles S. | director | 16250 0.3452% | $2.02 | 2 | 0 | |
| Kristal Robert Eugene | Chief Financial Officer | 7994 0.1698% | $2.02 | 3 | 0 | <0.0001% |
| Clark Mandy D. | VP of Operations | 0 0% | $2.02 | 0 | 1 |
Institutional Investor Ownership
No records found… | |||||||